Ceftriaxone
Structural formula | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||||||||
Non-proprietary name | Ceftriaxone | |||||||||||||||||||||
other names |
(6 R , 7 R ) -7 - {[(2 Z ) -2- (2-Amino-1,3-thiazol-4-yl) -2- (methoxyimino) acetyl] amino} -3 - {[( 2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl) sulfanyl] methyl} -8-oxo-5-thia-1-azabicyclo [4.2 .0] oct-2-en-2-carboxylic acid ( IUPAC ) |
|||||||||||||||||||||
Molecular formula | C 18 H 18 N 8 O 7 S 3 | |||||||||||||||||||||
Brief description |
white to light yellow powder (disodium ceftriaxone hemiheptahydrate) |
|||||||||||||||||||||
External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
Drug information | ||||||||||||||||||||||
ATC code | ||||||||||||||||||||||
Drug class | ||||||||||||||||||||||
Mechanism of action | ||||||||||||||||||||||
properties | ||||||||||||||||||||||
Molar mass | 554.58 g · mol -1 | |||||||||||||||||||||
Melting point |
> 155 ° C (decomposition) (disodium ceftriaxone hemiheptahydrate) |
|||||||||||||||||||||
safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
Toxicological data | ||||||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Ceftriaxone is an antibiotic from the group of cephalosporins of the 3rd generation. The bactericidal effect is, as with other β-lactam antibiotics by inhibiting bacterial cell wall synthesis. Ceftriaxone was introduced by Hoffmann-La Roche in 1982 .
Spectrum of activity
Compared to the 1st and 2nd generation cephalosporins, the spectrum of activity is slightly expanded in the gram- negative range and slightly weakened in the gram-positive range . The enterococcal gap typical of cephalosporins is present in ceftriaxone, and Listeria , Legionella and Pseudomonas aeruginosa are not recorded.
Pharmacokinetics
Since ceftriaxone is not absorbed after oral administration, it is administered parenterally . Due to the high plasma protein binding , the half-life of ceftriaxone is 7–8 hours. 60% of the excretion is via the kidneys and 40% via the bile . Ceftriaxone has very good tissue penetration and also reaches therapeutically effective concentrations in the cerebrospinal fluid .
Indications
Ceftriaxone is suitable for the calculated initial therapy of the most severe, life-threatening infections , including purulent meningitis . However, spectrum gaps must be closed by combining them with other antibiotics. Ceftriaxone is also suitable for the therapy of neuroborreliosis and the single treatment of gonorrhea .
Contraindications
Ceftriaxone is contraindicated in case of allergy to cephalosporins. Caution should also be exercised in the case of penicillin allergies because of a possible cross allergy . Because of the risk of bilirubin encephalopathy, premature babies and newborns should not be given ceftriaxone - an alternative third-generation cephalosporin would then be cefotaxime .
Interactions
Ceftriaxone infusions must not be administered at the same time as calcium -containing solutions and drugs, not even via separate cannulas. In addition, calcium-containing agents may only be administered 48 hours after the last dose of ceftriaxone, otherwise dangerous calcium-ceftriaxone precipitates may form. A combination with the antibiotic chloramphenicol should be avoided, as the two drugs mutually reduce their effectiveness.
Trade names
Cefotrix (D, A), Rocephin (D, A, CH), Tercefon (A), numerous generics (D, A, CH)
Individual evidence
- ↑ a b c data sheet Ceftriaxone disodium salt hemi (heptahydrate) from Sigma-Aldrich , accessed on March 16, 2011 ( PDF ).
- ^ The Merck Index . An Encyclopaedia of Chemicals, Drugs and Biologicals . 14th edition, 2006, pp. 322-323, ISBN 978-0-911910-00-1 .
- ^ Entry on ceftriaxone. In: Römpp Online . Georg Thieme Verlag, accessed on September 30, 2014.
- ↑ Ernst Mutschler, Monika Schäfer-Korting a. a .: Textbook of pharmacology and toxicology . 8th, completely revised and expanded edition. Wissenschaftliche Verlagsgesellschaft Stuttgart 2001. ISBN 3-8047-1763-2 . P. 797.